Yiling Pharmaceutical's nasal drug gains national medical insurance coverage

Shijiazhuang Yiling Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Beijing Yiling Pharmaceutical Co., Ltd., has successfully negotiated the inclusion of its exclusive product, Qifang Bitong Tablets, into the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalog (2025 Edition)." This marks the first time this Class I innovative traditional Chinese medicine, used for treating persistent allergic rhinitis, has been included in the catalog.

The drug is a unique traditional Chinese medicine classified as "Nasal Diseases ZF02." The medical insurance payment standard is set at yuan 1.78 per tablet (0.47g, equivalent to 1.52g of herbal pieces), with an agreement valid from January 1, 2026, to December 31, 2027. The company holds independent and complete intellectual property rights for Qifang Bitong Tablets.

This inclusion, along with 11 other exclusive patented traditional Chinese medicine products from the company already in the catalog, is expected to enhance market promotion and increase sales, positively impacting Yiling Pharmaceutical's long-term operations. The company notes that the short-term impact on its operating performance is currently difficult to estimate and is not expected to be significant.